°°°°°°°°^^^^^^^^^^^^^KAUFRAUSCH ^^^^^^^^^^^^°°°°°°°°°°°°°°°°°°° - 500 Beiträge pro Seite

[TheAndy]

Über 1940 liegen beim NASDAQ COMP. die SL der SHORTIS

Es wird knallen
Seht hier mal rein
Thread: Kein Titel für Thread 251215600
gruß
andy

[CBR900RR]

So So !

Quelle ?!?

[TheAndy]

CBR900RR
Shortis legen immer die SL knapp über die markanten Punkte.

Look.



Der Nasdaq Comp. hat exakt wie ich am 26.11.01 um 20:24:36 geschrieben habe ins Plus gedreht.
Im anderen Thread hatte ich ein ZIel von 1943 genannt.
das war nur 2 Punkte daneben.
Der Schlußstand liegt bei 1941

Sehe Dir den Stochastik an MEGA LONG
Sehe Dir den MA9 an, das ist der Trend
Sehe Dir im anderen Thread den Wochencandlechart an und besonders die Überschrift

Gruß
andy

TIP
Hunzinger 609710
Lycos 932728
Tria 744360
Telesens 529970
MME 576115

[TheAndy]

Eine Weltneuheit bei Calypte 909402

Calypte Biomedical Signs Key Agreement to Develop New Urine-based Test; Will Diagnose HIV Infection in as Little as 15 Minutes


ALAMEDA, Calif., Nov 23, 2001 (BW HealthWire) -- Calypte Biomedical Corp.
(OTCBB: CALY) today announced it has signed a key agreement with San
Antonio-based SA Scientific Inc., a privately held company, to develop a new
urine-based rapid HIV-1/2 antibody test that can provide results in as little as
15 minutes.

"Our expanding relationship with a company like SA Scientific, that has both
rapid test development experience and extensive manufacturing capabilities, in
conjunction with our expertise in urine HIV testing, will allow us to even more
effectively address the global threat of HIV/AIDS," said Calypte Biomedical`s
President, CEO and CFO Nancy E. Katz.

"We believe that Calypte`s existing urine-based HIV testing products are already
particularly well-suited for use in developing countries. The added advantages
of a rapid test will be even more attractive for use both here in the U.S. and
in developing countries where fully equipped laboratories or even basic testing
infrastructure is often lacking."

Calypte and SA Scientific expect that their one-step, urine-based rapid HIV test
will provide safe, cost-effective, painless results within that 15 minute period
without the need for lengthy or complex laboratory analysis. By comparison,
depending on a given lab`s workflow and efficiency, standard HIV tests can take
weeks to process, and also require a patient`s telephone contact or return visit
to obtain their test results.

The companies expect to manufacture the product at SA Scientific`s Texas
facilities, which are FDA and USDA registered, and certified for ISO 9001. SA
Scientific also will work with Calypte to facilitate FDA clearance for marketing
of the rapid HIV urine test in the United States. In light of a potentially
lengthy FDA review process, initial distribution in offshore markets is
anticipated. At that point, Calypte and SA Scientific expect the assay to be the
first urine-based rapid HIV antibody test on the market.

Calypte and SA Scientific have already been informally collaborating in adapting
SA Scientific`s proprietary rapid test platform to a urine HIV-1/2 test format,
with encouraging results. As a result, the formal agreement that has now been
reached continues development with the goal of a long-term relationship to
include the manufacture and distribution of the product, once development is
completed.

The test is intended for administration by trained healthcare professionals in
clinical settings, and will be similar in function to SA Scientific`s home
pregnancy tests, which also use urine as the sample fluid. Calypte already
produces the only FDA approved HIV-1 antibody urine tests.

Urine testing in general offers significant advantages over traditional HIV
blood tests and oral fluid-based tests because no special training is required
to collect urine samples, and inadequate sample collection is unlikely to be an
issue. In addition, the safety of both the patient and healthcare personnel are
enhanced because the urine of HIV-infected people does not appear to harbor the
infectious virus itself -- only the harmless antibody that signifies prior
exposure to HIV.

According to information provided by the U.S. National Institutes of Health,
there is no evidence that HIV is spread through urine. Perhaps most importantly,
studies in the U.S. and elsewhere have demonstrated that people are
significantly more willing to be tested by urine than by blood. Once the urine
sample has been collected, it can also be assayed for a variety of other
HIV-pertinent conditions, such as pregnancy, drug abuse, and other STDs such as
gonorrhea and Chlamydia.

The Centers for Disease Control (CDC) has called for the development of rapid
HIV tests as part of its "HIV Prevention Strategic Plan Through 2005," since
such tests could provide patients with on the spot results. "Calypte supports
the CDC initiative to make rapid HIV testing available to health professionals
worldwide as part of the effort in arresting the spread of HIV," Katz said.

SA Scientific Inc., founded in 1984, is a manufacturer of rapid one-step
diagnostic tests for both the U.S. and nearly 80 countries in the international
market. Their products include tests for pregnancy and infectious diseases such
as Strep A, adenovirus rotavirus and food pathogens such as E. coli and
salmonella.

Calypte Biomedical Corp., headquartered in Alameda, is a public healthcare
company dedicated to the development and commercialization of urine-based
diagnostic products and services for Human Immunodeficiency Virus Type 1
(HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s
tests include the screening EIA and supplemental Western Blot tests, the only
two FDA-approved HIV-1 antibody tests that can be used on urine samples. The
company believes that accurate, non-invasive urine-based testing methods for HIV
and other infectious diseases may make important contributions to public health
by helping to foster an environment in which testing may be done safely,
economically, and painlessly. Calypte markets its products in countries
worldwide through international distributors and strategic partners.

Statements in this press release that are not historical facts are
forward-looking statements, including statements regarding future revenues and
sales projections, plans for future financing, the ability to meet operational
milestones, marketing arrangements and plans, and shipments to and regulatory
approvals in international markets. Such statements reflect management`s current
views, are based on certain assumptions and involve risks and uncertainties.
Actual results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to, our ability
to obtain additional financing that will allow us to continue our current and
future operations and whether demand for our product and testing service in
domestic and international markets will continue to expand. The Company
undertakes no obligation to publicly update these forward-looking statements to
reflect events or circumstances that occur after the date hereof or to reflect
any change in the Company`s expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. Factors that may impact
the Company`s success are more fully disclosed in the Company`s most recent
public filings with the U.S. Securities and Exchange Commission ("SEC"),
including its annual report on Form 10-K for the year ended Dec. 31, 2000 and
its subsequent filings with the SEC.